IMPROVE-IT
Improved Reduction of Outcomes: Vytorin Efficacy International Trial
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.
N
18.144
Design
Double-blind RCT, median 6 yr
Endpunkt
Composite CV events
Relevanz
2
Ergebnis32.7 % vs 34.7 % (HR 0.94). Mean LDL 54 vs 70 mg/dL.
Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397. 10.1056/NEJMoa1410489
Diskussion & Kritik
First non-statin LDL trial to show outcome benefit — validated the 'lower-is-better' LDL hypothesis. Modest absolute risk reduction; cost-effectiveness debated.